Literature DB >> 3079602

Specific methods to identify plasma binding abnormalities in euthyroid hyperthyroxinemia.

J R Stockigt, S A Dyer, V S Mohr, E L White, J W Barlow.   

Abstract

Methods to identify the plasma T4-binding abnormalities that can cause euthyroid hyperthyroxinemia were evaluated in patients with excess T4-binding globulin, familial dysalbuminemic hyperthyroxinemia, prealbumin-associated hyperthyroxinemia, and autoantibody binding of T4. Familial dysalbuminemic hyperthyroxinemic serum showed a unique persistence of abnormal [125I]T4 binding when diluted 1:100 in phosphate buffer with added 1000-fold excess of unlabeled T4 (10(-6) M T4). Immunoprecipitation of [125I]T4 by antibody to prealbumin, precipitation of [125I]T4 by polyethylene glycol 6000 19%, and in vitro resin uptake of T3 were specific for prealbumin-associated hyperthyroxinemia, autoantibody binding of T4, and T4-binding globulin excess, respectively. These simple methods facilitate investigation of patients with euthyroid hyperthyroxinemia and will identify individuals and families at risk of misdiagnosis by standard methods. Use of these techniques rules out the known binding abnormalities in hyperthyroxinemic patients and may make the diagnosis of generalized hormone resistance more specific.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3079602     DOI: 10.1210/jcem-62-1-230

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  2 in total

1.  A four generation study of familial dysalbuminemic hyperthyroxinemia: diagnosis in the presence of an acquired excess of thyroxine-binding globulin.

Authors:  P P Yeo; Y Yabu; J R Etzkorn; R Rajatanavin; L E Braverman; S H Ingbar
Journal:  J Endocrinol Invest       Date:  1987-02       Impact factor: 4.256

2.  A point mutation in transthyretin increases affinity for thyroxine and produces euthyroid hyperthyroxinemia.

Authors:  A C Moses; H N Rosen; D E Moller; S Tsuzaki; J E Haddow; J Lawlor; J J Liepnieks; W C Nichols; M D Benson
Journal:  J Clin Invest       Date:  1990-12       Impact factor: 14.808

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.